Biotechnology firm Biogen Inc. (NASDAQ: BIIB) reported lower earnings, on an adjusted basis, and revenues for the second quarter of 2023. Total
BIIB Earnings: A snapshot of Biogen’s Q2 2023 financial results
Categories
pharmaceuticals
A look at the factors that influenced UnitedHealth’s Q2 earnings
Health insurance company UnitedHealth Group (NYSE: UNH) reported strong second-quarter results last week, triggering a stock rally. The company also strengthened its
Earnings Preview: Here’s what to expect from Johnson & Johnson’s Q2
Healthcare conglomerate Johnson & Johnson (NYSE: JNJ) entered a new phase recently after spinning off its consumer business. The move is part
Infographic: Highlights of UnitedHealth Group’s (UNH) Q2 2023 earnings
Diversified healthcare company UnitedHealth Group (NYSE: UNH) reported higher earnings and revenues for the second quarter of 2023. The company also raised
Earnings: AngioDynamics (ANGO) reports higher adj. profit for Q4; revenue up 5%
Medical device company AngioDynamics Inc. (NASDAQ: ANGO) on Wednesday reported an increase in adjusted profit for the fourth quarter of 2023, aided
Ocean Biomedical focuses its malaria program to address chronic malaria crisis in sub-Saharan Africa
Biopharma company Ocean Biomedical, Inc. (NASDAQ: OCEA) on Tuesday said it is focusing its multi-pronged malaria program to address the chronic malaria
Apogee Therapeutics set to go public. Here’s what you need to know
The US IPO market has remained mostly sluggish so far this year, continuing the weakness experienced in 2022. Meanwhile, there is speculation
Rite Aid Corp. (RAD) Q1 2024 adj. loss narrows; revenue down 6%
Drugstore chain Rite Aid Corporation (NYSE: RAD) announced first-quarter results, reporting lower revenues and a narrower adjusted loss. First-quarter loss, excluding special
Walgreens Boots Alliance (WBA) Q3 adj. profit rises on higher revenues
Walgreens Boots Alliance, Inc. (NASDAQ: WBA) on Tuesday said its third-quarter sales rose 9%. As a result, the healthcare service company’s adjusted
Superlatus names Dr. Eugenio Bortone COO; interim CEO Tim Alford to become CCO
Superlatus, Inc., a holding company of food products and distribution capabilities, on Tuesday, announced new appointments to its management team. The company
Ocean Biomedical (OCEA) joins the Russell 2000 Index
Ocean Biomedical, Inc. (NASDAQ: OCEA) on Tuesday said it has been included in the Russell 2000 Index and the broad-market Russell 3000
Ocean Biomedical granted US patent for bispecific cancer immunotherapy treatment
Biotechnology company Ocean Biomedical, Inc. (NASDAQ: OCEA) on Monday said its scientific co-founder Dr. Jack Elias has been granted a new, broad
Superlatus to be acquired by TRxADE HEALTH to create a global food consolidation platform
Superlatus, Inc., a U.S.-based holding company of food products and distribution capabilities, has signed a letter of intent to be acquired by
Ocean Biomedical extends patent rights for idiopathic pulmonary fibrosis discovery to Europe
Biopharma company Ocean Biomedical, Inc. (NASDAQ: OCEA) on Friday revealed that its scientific co-founder Dr. Jack Elias has received notice from the
Fundamental Research Corp. raises Ocean Biomedical’s price target to $17.63 per share
Ocean Biomedical, Inc. (NASDAQ: OCEA) on Wednesday said that Fundamental Research Corp. increased the price target of the company’s stock to $17.63
Earnings Summary: A snapshot of Catalent’s Q3 2023 results
Catalent, Inc. (NYSE: CTLT), a provider of delivery technologies and development solutions to the pharmaceutical industry, has reported earnings for the third
Ocean Biomedical’s scientific co-founder Dr. Jonathan Kurtis gets new patent for malaria vaccine
Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharmaceutical company focused on clinical programs in oncology, fibrosis, and infectious disease, Thursday said its scientific
Earnings Summary: CooperCompanies (COO) reports Q2 2023 financial results
Medical device maker CooperCompanies (NYSE: COO) has announced financial results for the second quarter of 2023, reporting lower earnings despite an increase
Taglich Brothers initiates coverage of Ocean Biomedical, with price target of $20
Biopharma company Ocean Biomedical, Inc. (NASDAQ: OCEA) on Thursday revealed that Taglich Brothers initiated coverage on the company with a share price
Ocean Biomedical, Inc. (NASDAQ: OCEA) Research Summary
Ocean Biomedical, Inc. (NASDAQ: OCEA) is a biopharmaceutical company focused on clinical programs in oncology, fibrosis, infectious disease, and inflammation. Its business
Ocean Biomedical (OCEA) set to join the Russell 2000 Index
Biopharmaceutical company Ocean Biomedical (NASDAQ: OCEA) on Thursday said it is expected to be added to the Russell 2000 Index, effective after